myriad_S_stacked.png
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
November 29, 2022 16:05 ET | Myriad Genetics, Inc.
Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) --  Myriad Genetics,...
myriad_S_stacked.png
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
November 17, 2022 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can...
myriad_S_stacked.png
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
November 14, 2022 08:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and...
myriad_S_stacked.png
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
November 10, 2022 08:00 ET | Myriad Genetics, Inc.
UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source. SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) --...
myriad_S_stacked.png
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
November 03, 2022 18:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a...
myriad_S_stacked.png
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
November 01, 2022 09:10 ET | Myriad Genetics, Inc.
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn baby’s gender from home – earliest...
myriad_S_stacked.png
Myriad Genetics Reports Third Quarter Financial Results
November 01, 2022 09:05 ET | Myriad Genetics, Inc.
Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3...
myriad_S_stacked.png
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
October 31, 2022 16:30 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its...
myriad_S_stacked.png
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
October 26, 2022 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on...
myriad_S_stacked.png
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
September 28, 2022 09:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted...